β3-Adrenoreceptor Blockade Induces Stem Cells Differentiation in Melanoma Microenvironment

Area of Science:

• Cancer biology
• Tumor microenvironment (TME) research
• Adrenergic signaling in cancer

Background:

• Cancer stem cell (CSC) niches within the TME are critical for tumor progression, but regulatory mechanisms remain incompletely understood.
• While β2-adrenergic receptors (β2-ARs) are known to promote tumor growth, the role of β3-adrenergic receptor (β3-AR) is an emerging area of interest.
• Previous research indicates β3-AR activation promotes melanoma malignancy via inflammation, angiogenesis, and immunotolerance by activating stromal cells.

Purpose of the Study:

• To investigate the effect of pharmacological β3-AR blockade on cancer stem cell markers and stromal cell differentiation in a melanoma model.
• To elucidate the impact of β3-AR antagonism on hematopoietic and mesenchymal stem cell populations within the tumor microenvironment.

Main Methods:

• Utilized B16 melanoma-bearing mice.
• Administered the β3-AR antagonist SR59230A.
• Performed cytofluorimetric analysis (FACS) on tumor masses to assess cell populations and differentiation markers.

Main Results:

• Pharmacological β3-AR blockade reduced cancer stem cell marker expression.
• β3-AR antagonism induced hematopoietic differentiation, increasing lymphoid/HSCs, myeloid progenitor/HSCs, Ter119+, NK precursor, and granulocyte precursor cells.
• β3-AR blockade promoted mesenchymal stem cell (MSC) differentiation into adipocytes, reducing stem cell pool renewal.

Conclusions:

• β3-AR blockade in the TME induces differentiation of various stromal cells, diminishing stemness traits.
• This differentiation effect suggests a potential therapeutic strategy for controlling melanoma progression by targeting β3-AR signaling.